echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The world's first FcRn antagonist is about to be launched in China, bringing new hope to 200,000 patients

    The world's first FcRn antagonist is about to be launched in China, bringing new hope to 200,000 patients

    • Last Update: 2022-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Yaodu Written by: Xiaoguang Editor: Maruko

    1

    Current status of myasthenia gravis treatment

    Myasthenia gravis is a rare, chronic autoimmune disease caused by dysfunction of neuromuscular junction transmissio.


    Efgartigimod brings new breakthrough in MG treatment


    Overview of the domestic distribution of FcRn inhibitors

    FcRn becomes another potential blockbuster target in the field of autoimmunity


    2 Ushibi - rozanolixizumab

    3 and Platinum Medicine/HanAll Biopharma - Bartolimumab

    refer to:

    https://https://FDA Approves Soliris® (Eculizumab) for the Treatment of Patients with Generalized Myasthenia Gravis (gM.


    https:// ht.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.